Results 21 to 30 of about 11,686 (228)
Translational Oncology, 2016 OBJECTIVE: To assess the effect of hyperthermic intraperitoneal chemotherapy (HIPEC) to eradicate intraperitoneal free cancer cells and to explore the feasibility of cytological cure for peritoneal carcinomatosis (PC).
Zhonghe Ji +5 more
doaj +1 more source
Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis. [PDF]
, 2018 Peritoneal metastasis (PM) is an advanced stage malignancy largely refractory to modern therapy. Intraperitoneal (IP) immunotherapy offers a novel approach for the control of regional disease of the peritoneal cavity by breaking immune tolerance.
Bowne, Wilbur B. +5 more
core +2 more sources
Intraperitoneal chemotherapy for peritoneal metastases : an expert opinion
, 2020 Introduction: The rationale for intraperitoneal (IP) drug delivery for patients with peritoneal metastases (PM) is based on the pharmacokinetic advantage resulting from the peritoneal-plasma barrier, and on the potential to adequately treat small, poorly
Braet, Helena +4 more
core +1 more source
Cytoreductive HIPEC-Combined Surgery in Treatment of Advanced Ovarian Cancer
Креативная хирургия и онкология, 2022 Background. Ovarian cancer ranks 5th in the structure of female oncological mortality in the Russian Federation, with a first-year post-diagnosis rate of almost 35%. In 75% cases, ovarian cancer is diagnosed at stages III—IV.
M. V. Zabelin +2 more
doaj +1 more source
Peritoneal carcinomatosis [PDF]
, 2013 Several gastrointestinal and gynecological malignancies have the potential to disseminate and grow in the peritoneal cavity. The occurrence of peritoneal carcinomatosis (PC) has been shown to significantly decrease overall survival in patients with liver
Ansaloni L +10 more
core +1 more source
Intraperitoneal chemotherapy for gastric cancer with peritoneal carcinomatosis: is HIPEC the only answer? [PDF]
, 2014 Gastric cancer with peritoneal carcinomatosis is notorious for its dismal prognosis. While the pathophysiology of peritoneal dissemination is still controversial, the rapid downhill course is universal.
Kwong, DLW, Lam, KO, Law, BTT, Law, SYK
core +1 more source
Serum procalcitonin improves diagnosis of infectious complications after CRS/HIPEC
World Journal of Surgical Oncology, 2023 Background Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) improve the survival of selected patients with peritoneal metastasis. A major cause of treatment-related morbidity after CRS/HIPEC is infection and sepsis. HIPEC
Lilian Roth +6 more
doaj +1 more source
World Journal of Surgical Oncology, 2020 Background Comprehensive readmission morbidity studies after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are scarce. This study aimed to investigate readmissions and in-hospital morbidity after CRS and HIPEC. Methods
Paul Dranichnikov +2 more
doaj +1 more source
Investigation of the Possible Functions of PACAP in Human Trophoblast Cells [PDF]
, 2014 Pituitary adenylate cyclase activating polypeptide (PACAP) is an endogenous neuropeptide having a widespread distribution both in the nervous system and peripheral organs including the female reproductive system.
Barakonyi, A. +10 more
core +1 more source
International Journal of Hyperthermia, 2020 Background Acute renal impairment (ARI) is a major complication after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for cancer patients with peritoneal metastases.
Chao-Yu Chen +11 more
doaj +1 more source